These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
647 related articles for article (PubMed ID: 15018597)
1. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Evans HC; Perry CM; Faulds D Drugs; 2004; 64(6):649-78. PubMed ID: 15018597 [TBL] [Abstract][Full Text] [Related]
2. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482 [TBL] [Abstract][Full Text] [Related]
3. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Lassen MR; Mouret P; Rosencher N; Kälebo P; Panfilov S; Eskilson C; Andersson M; Freij A; J Thromb Haemost; 2003 Dec; 1(12):2490-6. PubMed ID: 14675083 [TBL] [Abstract][Full Text] [Related]
4. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Eriksson BI; Agnelli G; Cohen AT; Dahl OE; Mouret P; Rosencher N; Eskilson C; Nylander I; Frison L; Ogren M; Thromb Haemost; 2003 Feb; 89(2):288-96. PubMed ID: 12574809 [TBL] [Abstract][Full Text] [Related]
5. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery. Colwell C; Mouret P Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914 [TBL] [Abstract][Full Text] [Related]
6. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Eriksson BI Thromb Res; 2003 Jul; 109 Suppl 1():S23-9. PubMed ID: 12818631 [TBL] [Abstract][Full Text] [Related]
8. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Eriksson BI; Bergqvist D; Kälebo P; Dahl OE; Lindbratt S; Bylock A; Frison L; Eriksson UG; Welin L; Gustafsson D; Lancet; 2002 Nov; 360(9344):1441-7. PubMed ID: 12433510 [TBL] [Abstract][Full Text] [Related]
9. Ximelagatran: an orally active direct thrombin inhibitor. Gulseth MP Am J Health Syst Pharm; 2005 Jul; 62(14):1451-67. PubMed ID: 15998925 [TBL] [Abstract][Full Text] [Related]
10. Clinical experience with ximelagatran in orthopaedic surgery. Eriksson B Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625 [TBL] [Abstract][Full Text] [Related]
11. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. Colwell CW; Berkowitz SD; Davidson BL; Lotke PA; Ginsberg JS; Lieberman JR; Neubauer J; McElhattan JL; Peters GR; Francis CW J Thromb Haemost; 2003 Oct; 1(10):2119-30. PubMed ID: 14521593 [TBL] [Abstract][Full Text] [Related]
12. [The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement]. Mouret P Hamostaseologie; 2002 Aug; 22(3):21-4. PubMed ID: 12215757 [TBL] [Abstract][Full Text] [Related]
13. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy. Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594 [TBL] [Abstract][Full Text] [Related]
14. Ximelagatran--a promising new drug in thromboembolic disorders. Petersen P Curr Pharm Des; 2005; 11(4):527-38. PubMed ID: 15725069 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Eriksson UG; Mandema JW; Karlsson MO; Frison L; Gisleskog PO; Wählby U; Hamrén B; Gustafsson D; Eriksson BI Clin Pharmacokinet; 2003; 42(7):687-701. PubMed ID: 12844328 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Heit JA; Colwell CW; Francis CW; Ginsberg JS; Berkowitz SD; Whipple J; Peters G; Arch Intern Med; 2001 Oct; 161(18):2215-21. PubMed ID: 11575978 [TBL] [Abstract][Full Text] [Related]
17. Oral direct thrombin inhibitors in clinical development. Gustafsson D J Intern Med; 2003 Oct; 254(4):322-34. PubMed ID: 12974871 [TBL] [Abstract][Full Text] [Related]
18. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations. Rosencher N Anaesthesia; 2004 Aug; 59(8):803-10. PubMed ID: 15270973 [TBL] [Abstract][Full Text] [Related]